Page 301 - Demo

General discussion299918. Blackston J, Chapple A, McGree J, McDonald S, Nikles J. Comparison of Aggregated N-of1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies. Healthcare. 2019.19. Mitchell GK, Hardy JR, Nikles CJ, Carmont SAS, Senior HE, Schluter PJ, et al. The effect of methylphenidate on fatigue in advanced cancer: An aggregated N-of-1 trial. J Pain Symptom Manage. 2015.20. Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, et al. Effect of Mexiletine on Muscle Stiffness in Patients with Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA - J Am Med Assoc. 2018;320(22). 21. OCEBM Levels of Evidence Working Group, Durieux N, Pasleau F, Howick J. The Oxford 2011 Levels of Evidence. Group. 2011.22. OCEBM Levels of Evidence Working Group, Jeremy Howick, Iain Chalmers (James Lind Library), Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton OG and MH. The Oxford levels of Evidence 2. Oxford Cent Evidence-Based Med. 2011.23. Stunnenberg BC, Berends J, Griggs RC, Statland J, Drost G, Nikles J, et al. N-of-1 Trials in Neurology A Systematic Review. Neurology. 2022;98(2). 24. Kazdin AE. Single-case experimental designs. Evaluating interventions in research and clinical practice. Behav Res Ther. 2019;117. 25. Nikles J, Onghena P, Vlaeyen JWS, Wicksell RK, Simons LE, McGree JM, et al. Establishment of an International Collaborative Network for N-of-1 Trials and Single-Case Designs. Contemp Clin Trials Commun. 2021;23. 26. Müller AR, Brands MM, van de Ven PM, Roes KC, Cornel MC, van Karnebeek CD, et al. The Power of 1: Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders. Neurology. 2021. 27. Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever happened to N-of-1 trials? Insiders’ perspectives and a look to the future. Milbank Q. 2008.28. Hartman AL. N-of-1 Trials in Rare Genetic Neurodevelopmental Disorders: Opportunities for Improvement. Vol. 96, Neurology. 2021. 29. Senn S. Mastering variation: Variance components and personalised medicine. Stat Med. 2016.30. Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2017. 31. Hessl D, Sansone SM, Berry-Kravis E, Riley K, Widaman KF, Abbeduto L, et al. The NIH Toolbox Cognitive Battery for intellectual disabilities: Three preliminary studies and future directions. J Neurodev Disord. 2016;8(1). 32. Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): Current perspectives. Therapeutics and Clinical Risk Management. 2019. 33. Shields RH, Kaat AJ, McKenzie FJ, Drayton A, Sansone SM, Coleman J, et al. Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology. 2020. 34. Ediebah DE, Reijneveld JC, Taphoorn MJB, Coens C, Zikos E, Aaronson NK, et al. Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res. 2017;26(4). 35. Alcantara J, Ohm J, Alcantara J. Comparison of pediatric self reports and parent proxy reports utilizing PROMIS: Results from a chiropractic practice-based research network. Complement Ther Clin Pract. 2017;29. 36. Burks HB, Des Bordes JKA, Chadha R, Holmes HM, Rianon NJ. Quality of life assessment in older adults with dementia: A systematic review. Vol. 50, Dementia and Geriatric Cognitive Disorders. 2021. 37. Griffiths AW, Smith SJ, Martin A, Meads D, Kelley R, Surr CA. Exploring self-report and proxyreport quality-of-life measures for people living with dementia in care homes. Qual Life Res. 2020;29(2). Annelieke Muller sHL.indd 299 14-11-2023 09:08